Indication: Glioma

NCCTG N0577/Endorsed Study: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

1p/19q codeleted anaplastic

Sub-indication: Grade 3 Astrocytoma, Glioma

Line of Therapy: First line, Newly diagnosed

Drug Study

Principal Investigator: Aaron Spalding, M.D.
Norton Cancer Institute

Sponsor: Radiation Therapy Oncology Group (RTOG)

Learn more at ClinicalTrials.gov

Email for more information: CNS-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.